Peptide vaccines for lung cancers expressing TTK, URLC10 or...

Details Peptide vaccines for lung cancers expressing TTK, URLC10 or... Peptide vaccines for lung cancers expressing TTK, URLC10 or...

2006-02-17

2010-12-07

Reddig, Peter J (Department: 1642)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

C530S328000

Reexamination Certificate

active

07847060

ABSTRACT:
The present invention provides peptides comprising the amino acid sequence of SEQ ID NO: 8, 67, 89, as well as peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, and having cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors comprising these peptides. The peptides of the present invention can also be used as vaccines.

REFERENCES:
patent: 2002/0086848 (2002-07-01), Kubbies et al.
patent: 2003/0022858 (2003-01-01), Kubbies et al.
patent: 2003/0045491 (2003-03-01), Reinhard et al.
patent: 2003/0105000 (2003-06-01), Pero et al.
patent: 2003/0232350 (2003-12-01), Afar et al.
patent: 2003/0236209 (2003-12-01), Foy et al.
patent: 2004/0005563 (2004-01-01), Mack et al.
patent: 2005/0186610 (2005-08-01), Lee et al.
patent: 2006/0024692 (2006-02-01), Nakamura et al.
patent: 1854473 (2007-01-01), None
patent: 2000-510002 (2000-08-01), None
patent: 2005-523688 (2005-08-01), None
patent: 2005-230011 (2005-09-01), None
patent: 2005-525789 (2005-09-01), None
patent: 2005-531280 (2005-10-01), None
patent: 2006-500949 (2006-01-01), None
patent: 2007-506443 (2007-03-01), None
patent: WO 98/45428 (1998-10-01), None
patent: WO 99/46594 (1999-09-01), None
patent: WO 01/72775 (2001-10-01), None
patent: WO 02/30268 (2002-04-01), None
patent: WO 02/068444 (2002-09-01), None
patent: WO 02/086443 (2002-10-01), None
patent: WO 03/038130 (2003-05-01), None
patent: WO 03/042661 (2003-05-01), None
patent: WO 03/062395 (2003-07-01), None
patent: WO 03/086175 (2003-10-01), None
patent: WO 2004/031413 (2004-04-01), None
patent: WO 2005/002509 (2005-01-01), None
patent: WO 2005/073374 (2005-08-01), None
patent: WO 2006/093337 (2006-09-01), None
Celis (J of Clinical Investigation, 2002, 110:1765-1768).
Marincola et al. (Trends in Immunology, Jun. 2003, 334-341).
Kirkin et al. (1998, APMIS, 106: 665-679).
Sherman et al. (Critical Reviews in Immunol. 1998, 18:47-54).
George et al. (2005, Trends in Immunology 26(12):653-659).
Smith (Clin. Immunol, 1994, 41(4): 841-849).
Harlin et al. (Caner Immunol. Immunotherap. 2006, 55:1185-1197).
Gura (Science, 1997, 278:1041-1042).
Kaiser (Science 2006, 31: 1370).
Bowie et al (Science, 1990, 247:1306-1310).
Skolnick et al. (TIBTECH 18:34-39, 2000).
Ibragimova and Eade (Biophysical Journal, Oct. 1999, vol. 77, pp. 2191-2198).
Rudikoff et al. (PNAS, USA, 1982, 79: 1979-1983).
Coleman et al. (Research in Immunology, 1994; 145(1): 33-36).
Abaza et al. (Journal of Protein Chemistry, vol. 11, No. 5, 1992, pp. 433-444).
Adams, H-P., “Prediction of binding to MHC class I molecules,”Journal of Immunological Methods, vol. 185(2), pp. 181-190 (Sep. 25, 1995).
Schueler-Furman, O., et al., “Structure-based prediction of binding peptides to MHC class I molecules: Application to a broad range of MHC alleles,”Protein Science, vol. 9(9), pp. 1838-1846 (Sep. 2000).
Tokunaga, K., et al., “Sequence-based association analysis of HLA class I and II alleles in Japanese supports conservation of common haplotypes,”Immunogenetics, vol. 46(3), pp. 199-205 (1997).
Kondo et al.; “Prominent roles of secondary anchor residues in peptide binding to HLA-A24 human class 1 molecules”; 1995;J. Immunol.; vol. 155, No. 9, pp. 4307-4312.
Kubo et al.; “Definition of specific peptide motifs for four major HLA-A alleles”; 1994;J. Immunol.; vol. 152, No. 8, pp. 3913-3924.
Zaremba et al.; “Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen”; 1997;Cancer Res.; vol. 57, pp. 4750-4757.
Mills, G., et al., “Expression of TTK, a novel human protein kinase, is associated with cell proliferation,”The Journal of Biological Chemistry, vol. 267(22), pp. 16000-16006 (1992).
Wang, T., et al., “Identification of genes using differentially over-expressed in lung squamous cell carcinoma using combination of cDNA subtraction and microarray analysis,”Oncogene, vol. 19, pp. 1519-1528 (2000).
Schmandt et al., “IL-2 induced expression of TTK, a serine, threonine, tyrosine kinase, correlates with cell cycle progression”;J. Immunol.; 152: 96-105 (1994).
Stucke et al.; “Human Mps1 kinase is required for the spindle assembly checkpoint not for centrosome duplication”;EMBO J.; 21(7): 1723-1732 (2002).
Wiess et al.; “TheSaccharomyces cerevisiaespindle pole body duplication gene MPS1 is a part of the mitotic checkpoint”;J. Cell. Biol.; 132(1-2): 111-123 (1996).
Winey et al.; “MPS1andMPS2: Novel yeast genes defining distinct steps of spindle pole body duplication”;J. Cell. Biol.; 114(4): 745-754 (1991).
Rammensee, H-G, et al., “MHC ligands and peptide motifs: first listing,”Immunogenetics, vol. 41(4), pp. 178-228 (1995).

Affiliated with

Also associated with

Rating

Peptide vaccines for lung cancers expressing TTK, URLC10 or... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptide vaccines for lung cancers expressing TTK, URLC10 or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide vaccines for lung cancers expressing TTK, URLC10 or... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4178775